Jubilant Life Sciences has intraday target of Rs 183.50, says Ashish Tater, Fort Share Broking
Tater told CNBC-TV18, "Jubilant Life Sciences is undervalued by atleast 20% at current levels and we have a medium-term target of close to Rs 210 mark. Looking its business into Osteoporosis and others, this particular stock is definitely to get rerating and I have an intermediate target of close to Rs 210 mark and intraday target of close to Rs 183.50.
Click HERE to know the rules and follow the score card